Empower the fight against bladder cancer

Be a catalyst for change.

This unique investment opportunity is open to accredited investors.

Why invest in Theralase Technologies

To pave the road to commercialization and become the next standard of care for NMIBC

Multi-billion dollar opportunity
as bladder cancer is the 10th most common cancer in the world (6th in men)

Pelangio Exploration Logo


Closed Successfully

Raising | $1,500,000 CAD
Terms | $0.22 CAD per Unit
(1 full share + 1 full share warrant at $0.28 CAD for 5 years)

Join our mission to raise funds for the treatment of Non-Muscle Invasive Bladder Cancer, and be a catalyst for change in the fight against this devastating disease. Your investment not only has the potential to save lives, but it also promises substantial returns in the form of groundbreaking medical advancements, improved patient outcomes, and a world where bladder cancer is no longer a formidable adversary. By participating in this raise, you’re not just an investor; you’re a hero in the battle against cancer, and your support will have a lasting impact on countless individuals and their families. Together, we can make a real difference in the lives of those affected by Non-Muscle Invasive Bladder Cancer while creating a brighter future for all.

Join in on this exciting investment opportunity with Theralase Technologies

For more information, please enter your details below and someone from the Theralase Technologies team will be in touch.

Stockhouse logo

The information provided on this page is for informational purposes only and is not intended to provide specific financial or investment advice. The information provided on this page is not a solicitation to buy or sell securities. Stockhouse Publishing Ltd. (“Stockhouse”) is an online investor community that connects active investors and small cap public companies. Stockhouse is not registered as a broker, dealer, exempt market dealer, or any other registrant in any securities regulatory jurisdiction and will not be performing any registerable activity as defined by the applicable regulatory bodies. Please do your due diligence.

“Theralase® is currently conducting a Phase II NMIBC clinical study for regulatory approval in Canada and the United States. The Theralase® Anti-Cancer Therapy (“ACT”) is currently not Health Canada or FDA approved.

©Copyright 2023 Theralase Technologies Inc. All Rights Reserved.

View PresentationYes, I want to learn more

Get stock insights, analysis and discussion about Theralase Technologies (TSXV:TLT). Join the TLT discussion on Canada’s largest online investor community.

Join the Conversation

Theralase Technologies (TSXV:TLT)
By providing your email and clicking the button above, you consent to receiving communications from Theralase Technologies and Stockhouse. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices, please review our Privacy Policy.
Investor Presentation

About Theralase Technologies (TSXV:TLT)

Destroying Cancer at the Speed of Light®

Best-in-class treatment for NMIBC
(according to interim clinical data)

Theralase® is focused on commercialization of next generation Photo Dynamic Compounds (“PDCs”) for the treatment Non-Muscle Invasive Bladder Cancer (“NMIBC”).

Management Team

Roger Dumoulin-White
B.Sc, P. Eng, pro. dir.
President and CEO

Over 34 years leading multi-disciplinary teams in sales, marketing, finance, and more. Founder of Theralase Inc. in 1994.

Kristina Hachey
Chief Financial Officer, Director

20+ years in finance for public and private firms. Expert in corporate governance and compliance.

Arkady Mandel
MD, Ph.D., D.Sc.
Chief Scientific Officer

30+ years innovating medical laser applications, a pioneer in therapeutic dermatology, and clinical technology advancement.

Why Invest in TheralaseManagement TeamCEO InterviewRequest Information